Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C

American Journal of Gastroenterology

Volumn 95, Issue 4, 2000, Pages 1041-1050

  Kageyama, Fujito ^a   Kobayashi, Yoshimasa ^a   Kawasaki, Tsunehisa ^a   Toyokuni, Shinya ^b   Uchida, Koji ^c   Nakamura, Hirotoshi ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYNONENAL; INTERFERON; IRON; VIRUS RNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIPID PEROXIDATION; LIVER BIOPSY; MALE; PRIORITY JOURNAL; SIDEROSIS; VIRUS HEPATITIS;

ADULT; AGED; ALDEHYDES; BIOPSY; CROSS-LINKING REAGENTS; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; IRON; LIPID PEROXIDATION; LIVER; LIVER FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 0034113670     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(00)00771-1     Document Type: Article

References (39)

1. Esterbauer H., Schaur R.J., Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde and related aldehydes. Free Rad Biol Med. 11:1991;81-128.
2. Toyokuni S., Uchida K., Okamoto K., et al. Formation of 4-hydroxy-2-nonenal-modified protein in the renal proximal tubules of rats treated with a renal carcinogen, ferric nitrilotriacetate. Proc Natl Acad Sci USA. 91:1994;2616-2620.
3. Uchida K., Szweda L.I., Chae H.Z., et al. Immunodetection of 4-hydroxynonenal protein adducts in oxidized hepatocytes. Proc Natl Acad Sci USA. 90:1993;8742-8746.
4. Uchida K., Itakura K., Kawakishi S., et al. Characterization of epitopes recognized by 4-hydroxy-2-nonenal specific antibodies. Arch Biochem Biophys. 324:1995;241-248.
5. Britton R.S., Bacon B.R. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology. 41:1994;343-348.
6. Di Bisceglie A.M., Axiotis C.A., Hoofnagle J.H., et al. Measurements of iron status in patients with chronic hepatitis. Gastroenterology. 102:1992;2108-2113.
7. Piperno A., D'Alba R., Fargion S., et al. Liver iron concentration in chronic viral hepatitis A study of 98 patients . Eur J Gastroenterol Hepatol. 7:1995;1203-1208.
8. Haque S., Chandra B., Gerber M.A., et al. Iron overload in patients with chronic hepatitis C A clinicopathologic study . Hum Pathol. 27:1996;1277-1281.
9. Hayashi H., Takikawa T., Nishimura N., et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol. 89:1994;986-988.
10. Piperno A., Sampietro M., D'Alba R., et al. Iron stores, response to α-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver. 16:1996;248-254.
11. Fong T., Han S.H., Tsai N.C., et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to α-interferon in patients with chronic hepatitis C. J Hepatol. 28:1998;369-374.
12. Bonkovsky H.L., Banner B.F., Rothman A.L. Iron and chronic viral hepatitis. Hepatology. 25:1997;759-768.
13. Torrance J., Bothwell T.H. A simple technique for measuring storage iron concentrations in formalinized liver samples. S Afr J Med Sci. 33:1968;9-11.
14. Desmet V.J., Geber M., Hoofnagle J.H., et al. Classification of chronic hepatitis C Diagnosis, grading and staging . Hepatology. 19:1994;1513-1520.
15. Knodell R.G., Ishak K.G., Black W.C., et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1:1981;431-435.
16. Barton A.L., Banner B.F., Cable E.E., et al. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol. 103:1995;419-424.
17. Intra- and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 20:1994;15-20.
18. Boitnott J.K., Maddrey W.C. Alcoholic liver disease I. Interrelationships among histologic features and the histologic effects of prednisolone therapy . Hepatology. 1:1981;599-612.
19. Di Bisceglie A.M., Martin P., Kassianides C., et al. Recombinant interferon alfa therapy for chronic hepatitis C. N Engl J Med. 30:1989;1506-1510.
20. Di Bisceglie A.M., Bacon B.R., Kleiner D.E., et al. Increase in hepatic iron stores following prolonged therapy with ribavirin in patients with chronic hepatitis C. J Hepatol. 21:1994;1109-1112.
21. Recknagel R.O., Glende E.A., Dolak J.A. Mechanisms of carbon tetrachloride toxicity. Pharmacotherapy. 43:1987;139-154.
22. Chisari F.V., Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol. 13:1995;29-60.
23. Koziel M.J. The role of immune responses in the pathogenesis of hepatitis C virus infection. J Viral Hepat. 4:(suppl 2):1997;31-41.
24. Britton R.S. Metal-induced hepatotoxicity. Semin Liver Dis. 16:1996;3-11.
25. Kobune M., Kohgo Y., Kato J., et al. Interleukin-6 enhances hepatic transferrin uptake, and ferritin expression in rats. Hepatology. 19:1994;1468-1475.
26. Higueras V., Raya A., Rodrigo J.M., et al. Interferon decreases serum lipid peroxidation products of hepatitis C patients. Free Rad Biol Med. 16:1994;131-133.
27. Farinati F., Cardin R., De Maria N., et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol. 22:1995;449-456.
28. Maria N.D., Colantoni A., Fagiuoli S., et al. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Rad Biol Med. 21:1996;291-295.
29. Paradis V., Kollinger M., Fabre M., et al. In situ detection of lipid peroxidation by-products in chronic liver diseases. Hepatology. 26:1997;135-142.
30. Paradis V., Mathurin P., Kollinger M., et al. In situ detection of lipid peroxidation in chronic hepatitis C Correlation with pathological features . J Clin Pathol. 50:1997;401-406.
31. Mutlu-Turkoglu U., Ademoglu E., Turkoglu S., et al. The effects of interferon-α on serum lipid peroxidation and total thiol contents in patients with chronic active hepatitis C. Res Commun Mol Pathol Pharmacol. 96:1997;357-361.
32. Jurgens G., Lang J., Esterbauer H. Modification of human low-density lipoprotein by the lipid peroxidation product 4-hydroxynonenal. Biochim Biophys Acta. 875:1986;103-114.
33. Babior B.M. The respiratory burst of phagocytes. J Clin Invest. 73:1984;599-601.
34. Halliwell B., Gutteridge J.M.C. Free radicals and catalytic metal ions in human disease. Methods Enzymol. 186:1991;1-85.
35. O'Connell M.J., Ward R.J., Baum H., et al. The role of iron in ferritin- and haemosiderin-mediated lipid peroxidation in liposomes. Biochem J. 229:1985;135-139.
36. Jacobs A. Low molecular weight intracellular iron transport compounds. Blood. 50:1977;433-439.
37. Friedman S.L. The cellular basis of hepatic fibrosis Mechanisms and treatment strategies . N Engl J Med. 25:1993;1828-1835.
38. Parola M., Pinzani M., Casini A., et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen α1(I) gene expression in human liver fat storing cells. Biochem Biophys Res Commun. 194:1993;1044-1050.
39. Boucher E., Bourienne A., Adams P., et al. Liver iron concentration and distribution in chronic hepatitis C before and after interferon treatment. Gut. 41:1997;115-120.